Weed Week: In Thailand you’ll be able to grow cannabis ‘like any other herb’
Health & Biotech
Link copied to
Thailand has not yet legalised marijuana but pretty soon Thais will not only be able to grow their own plants but they will be allowed to sell them to the government.
“In the near future, families will be able to plant cannabis trees in their back gardens like any other herb,” Health Minister Anutin Charnvirakul said.
But if you’re American and you’d much rather try other people’s products, then becoming a cannabis tester might be the way to go.
As the cannabis sector grows so does the string of product reviews. You could do it for free – or you could be paid $US36,000 ($52,800) a year.
American Marijuana is accepting applications for anyone interested in becoming a professional cannabis critic. The company said: “this job is 100 per cent for real and it’s an important job”.
But it’s not just about consuming the products. The lucky candidate will also have to create digital content, vlogs and podcasts, including explainers about how the products work.
Heading back Down Under, a senate community affairs committee inquiry is about to receive submissions for an inquiry into the suitability of cannabis for subsidies through the Pharmaceutical Benefits Scheme.
But one government senator, Jonathon Duniam, claimed the Greens, the ones pushing for the inquiry, were ignoring the progress made to date.
It was a quiet week among ASX small caps. The biggest gainer was Suda Pharmaceuticals (ASX:SUD) which got a cash boost of nearly $1m with an R&D tax incentive refund.
Zelda Therapeutics (ASX:ZLD) announced it would take part in a 600-patient clinical trial which aims to reduce pain for advanced cancer sufferers.
And Althea’s (ASX:AGH) Bristol clinic secured a licence from the Care and Quality Commission (CQC) allowing it to now provide home care.
Here’s Stockhead’s latest summary of weekly and annual price performance for ASX-listed cannabis stocks:
Scroll or swipe to reveal table. Click headings to sort: